U.S. top court declines to hear patent case on glaucoma drug
WASHINGTON, March 31
WASHINGTON, March 31 (Reuters) - The U.S. Supreme Court on Monday left intact an appeals court ruling that endorsed patent protections for Combigan, Allergan Inc's glaucoma drug.
The high court declined to hear an appeal filed by Novartis AG's Sandoz Inc, which had challenged several patents held by Allergan that do not expire until 2022. Sandoz wanted to sell a generic version of the drug, which also is used to treat ocular hypertension.
In May 2013, the U.S. Court of Appeals for the Federal Circuit decision ruled in favor of Allergan.
The case is Sandoz v. Allergan, U.S. Supreme Court, 13-889. (Reporting by Lawrence Hurley; Editing by Howard Goller and Alden Bentley)
- Tweet this
- Share this
- Digg this
- Moscow fights back after sanctions; battle rages near Ukraine crash site |
- Insight - European regulators training sights on Google's mobile software
- Argentina braces for market reaction to second default in 12 years |
- Gaza toll soars as Israel 'days' from completing tunnel hunt |
- 'Complacent' NATO unprepared for Russian threat - MPs